These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 26396258)
1. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258 [TBL] [Abstract][Full Text] [Related]
2. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Ju W; Zhang M; Wilson KM; Petrus MN; Bamford RN; Zhang X; Guha R; Ferrer M; Thomas CJ; Waldmann TA Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1624-9. PubMed ID: 26811457 [TBL] [Abstract][Full Text] [Related]
3. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression. Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356 [TBL] [Abstract][Full Text] [Related]
5. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Ju W; Zhang M; Jiang JK; Thomas CJ; Oh U; Bryant BR; Chen J; Sato N; Tagaya Y; Morris JC; Janik JE; Jacobson S; Waldmann TA Blood; 2011 Feb; 117(6):1938-46. PubMed ID: 21106989 [TBL] [Abstract][Full Text] [Related]
6. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. Ishikawa C; Senba M; Mori N Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Chetoui N; Boisvert M; Gendron S; Aoudjit F Immunology; 2010 Jul; 130(3):418-26. PubMed ID: 20465565 [TBL] [Abstract][Full Text] [Related]
8. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells. Yamada O; Ozaki K; Akiyama M; Kawauchi K Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Tomita M; Kawakami H; Uchihara JN; Okudaira T; Masuda M; Matsuda T; Tanaka Y; Ohshiro K; Mori N Retrovirology; 2006 Apr; 3():22. PubMed ID: 16603085 [TBL] [Abstract][Full Text] [Related]
10. Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent. Aikawa A; Kozako T; Uchida Y; Yoshimitsu M; Ishitsuka K; Ohsugi T; Honda SI FEBS J; 2020 Sep; 287(18):4005-4015. PubMed ID: 32027454 [TBL] [Abstract][Full Text] [Related]
11. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin. Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431 [TBL] [Abstract][Full Text] [Related]
12. IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. Wang TT; Yang J; Zhang Y; Zhang M; Dubois S; Conlon KC; Tagaya Y; Hamele CE; Dighe S; Olson TL; Feith DJ; Azimi N; Waldmann TA; Loughran TP Leukemia; 2019 May; 33(5):1243-1255. PubMed ID: 30353031 [TBL] [Abstract][Full Text] [Related]
13. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435 [TBL] [Abstract][Full Text] [Related]
14. EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Moarbess G; El-Hajj H; Kfoury Y; El-Sabban ME; Lepelletier Y; Hermine O; Deleuze-Masquéfa C; Bonnet PA; Bazarbachi A Blood; 2008 Apr; 111(7):3770-7. PubMed ID: 18218850 [TBL] [Abstract][Full Text] [Related]
15. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265 [TBL] [Abstract][Full Text] [Related]
16. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615 [TBL] [Abstract][Full Text] [Related]
17. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Waldmann TA Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. Sharma ND; Nickl CK; Kang H; Ornatowski W; Brown R; Ness SA; Loh ML; Mullighan CG; Winter SS; Hunger SP; Cannon JL; Matlawska-Wasowska K Cancer Sci; 2019 Jun; 110(6):1931-1946. PubMed ID: 30974024 [TBL] [Abstract][Full Text] [Related]
20. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]